Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Bryan Ang, AAO 2021: Gel Stent for Open Angle Glaucoma

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Dec 16th 2021

It was wonderful to catch up with Bryan Ang (Tan Tock Seng Hospital, Novena, Singapore) about the Xen®45 (Allergan Inc., Irvine, CA, USA) and its use in treating open angle glaucoma.

Questions:

  1. What factors can cause failure of minimally invasive glaucoma surgery (MIGS)? (00:15)
  2. When  should bleb needling be considered during MIGS with the Xen45 gel stent? (01:23)
  3. What surgical tips would you like to share for the optimal way to perform bleb needling? (01:51)
  4. What should be considered if the IOP remains suboptimal despite multiple needling attempts? (02:38)
  5. What other factors should be considered to ensure postoperative success in open revision surgery? (03:35)

 

Speaker Disclosure: Bryan Ang has received consultant, research, travel, and speakers’ honoraria from Allergan/Abbvie.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.

Filmed in coverage of AAO 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup